-
PurposeRetroviral construct for expressing human EGFR with L747-E749 deletion and A750P mutation in human cells
-
Depositing Lab
-
Publication
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 11015 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepBABE puro
- Backbone size w/o insert (bp) 5169
-
Vector typeMammalian Expression, Retroviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameEGFR (del3)
-
Alt nameepidermal growth factor receptor
-
Alt nameERBB
-
SpeciesH. sapiens (human)
-
Insert Size (bp)3630
-
MutationL747-E749 deleted, A750P
-
Entrez GeneEGFR (a.k.a. ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS, PIG61, mENA)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site SnaBI (destroyed during cloning)
- 3′ cloning site SnaBI (destroyed during cloning)
- 5′ sequencing primer pBABE5' (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Author has deposited the sequence of the insert to Addgene. Click on "sequence" to view. Mutation made by using the following primers to PCR from plasmid 11011: 5'-GTCGCTATCAAGGAACCAACATCTCCGAAA-3' and 5'-TTTCGGAGATGTTGGTTCCTTGATAGCGAC-3'
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
EGFR (del3) L747-E749del, A750P was a gift from Matthew Meyerson (Addgene plasmid # 11015 ; http://n2t.net/addgene:11015 ; RRID:Addgene_11015) -
For your References section:
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. PLoS Med. 2005 Oct 4. 2(11):e313. 10.1371/journal.pmed.0020313 PubMed 16187797